{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T01:59:52Z","timestamp":1795226392506,"version":"4.10.3"},"reference-count":6,"publisher":"SLACK, Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pediatr Ophthalmol Strabismus"],"published-print":{"date-parts":[[2000,11]]},"abstract":"<jats:p>ABSTRACT<\/jats:p>\n          <jats:p>Purpose: To develop stable liquid dosage forms of levodopa-carbidopa for use In children with amblyopia.<\/jats:p>\n          <jats:p>Methods: Levodopa (100 mg) and carbidopa (25 mg) tablets were used to prepare the suspensions at 5 and 1 .25 mg\/mL, respectively. For each suspension, five bottles were stored at 250C and five at 40C. Three samples were taken from each bottle at 0, 7, 14, 28, 42, 56, 70, and 91 days (n=15). Levodopa-carbidopa concentrations for each sample were measured in duplicate by validated and stability-indicating high-performance liquid chromatographic method.<\/jats:p>\n          <jats:p>Results: The mean concentrations of levodopa-carbidopa in Ora Plus\/Ora Sweet suspensions were 96% and 92% of the Initial concentrations for 28 days at 25\u00b0C, and 94% and 93% for 42 days at 4\u00b0C. In the suspension containing ascorbic acid, the mean concentrations of levodopa-carbidopa were above 93% and 92% for 14 days at 25\u00b0C, and 93% and 92% for 28 days at 4\u00b0C. This liquid formulation was administered to 15 children (mean age: 5.6\u00b11.4 years) with amblyopia. The number and type of adverse effects were similar in the levo-dopa-carbidopa versus placebo group.<\/jats:p>\n          <jats:p>Conclusion: Levodopa-carbidopa in extemporaneous suspensions prepared in Ora Plus and Ora Sweet were stable for 28 days when stored at 25\u00b0C and for 42 days at 4\u00b0C. Our data suggest our liquid formulation may be used safely in children with amblyopia.<\/jats:p>\n          <jats:p>Journal of Pediatric Ophthalmology and Strabismus 2000;37:333-337.<\/jats:p>","DOI":"10.3928\/0191-3913-20001101-06","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T21:22:07Z","timestamp":1618867327000},"page":"333-337","source":"Crossref","is-referenced-by-count":12,"title":["Development of Two Stable Oral Suspensions of Levodopa-Carbidopa for Children With Amblyopia"],"prefix":"10.3928","volume":"37","author":[{"given":"Milap C","family":"Nahata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S","family":"Morosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence E","family":"Leguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_1","unstructured":"1. Singh A Tanner CM Wasserstein P Kunh M Tetrud J. Orally administered levodopa-carbidopa (LD-CD) solution reduces \"offtime\" in Parkinson's disease [abstract]. Neurology. 1993;43A197."},{"key":"e_1_3_1_3_1","unstructured":"2. Levodopa-carbidopa. In: McEvory GK ed. AHFS Drug Information. Bethesda Md: American Society of HealuVSystem Pharmacists; 1997:1864-1869."},{"key":"e_1_3_1_4_1","doi-asserted-by":"crossref","unstructured":"3. Kunh MC Tetrud JW Tanner CM et al. Double-blind placebocontrolled crossover study of duodenal infusion of levodopa\/carbidopa in Parkinson's disease patients with \"on-off\" fluctuations. Neurology 1993:43:1698-1703.","DOI":"10.1212\/WNL.43.9.1698"},{"key":"e_1_3_1_5_1","doi-asserted-by":"crossref","unstructured":"4. Pappen EJ Buhrfiend C. Lipton JW Carvey PM Stebbins GT Goetz CG. Levodopa stability in solution: dme course environmental effects and practical recommendations for clinical use. Mov Disord. 1996;11:24-26.","DOI":"10.1002\/mds.870110106"},{"key":"e_1_3_1_6_1","doi-asserted-by":"crossref","unstructured":"5. Kurth MC Tetrud JW Irwin I Lyness WH Langston JW Oral levodopa\/carbidopa solution versus tablets in Parkinson's disease patients with severe fluctuations: a pilot study. Neurology. 1993;43:1036-1039.","DOI":"10.1212\/WNL.43.5.1036"},{"key":"e_1_3_1_7_1","doi-asserted-by":"crossref","unstructured":"6. Leguige LE Rogers GI Walson PD Bremer DL McGregor ML. Occlusion and levodopa-carbidopa treatment for childhood amblyopia. JAAPOS. 1998;2:257-264.","DOI":"10.1016\/S1091-8531(98)90080-5"}],"container-title":["Journal of Pediatric Ophthalmology &amp; Strabismus"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T13:59:08Z","timestamp":1683035948000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/0191-3913-20001101-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["10.3928\/0191-3913-20001101-06"],"URL":"https:\/\/doi.org\/10.3928\/0191-3913-20001101-06","relation":{},"ISSN":["0191-3913","1938-2405"],"issn-type":[{"value":"0191-3913","type":"print"},{"value":"1938-2405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11]]}}}